SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of July 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
210, 1167 Kensington Cr. N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics
Biotech Inc. Treats
200th
Cancer Patient in Clinical Studies with REOLYSIN®
Company to Host Conference Call to Update Clinical Program
CALGARY, AB, July 14, 2008 Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY)
announced today that it has now enrolled and treated 200 cancer patients in clinical studies with
REOLYSIN®, its proprietary formulation of the human reovirus.
The clinical program has gained substantial momentum in the past year, culminating in the
treatment of our 200th patient this week, said Dr. Brad Thompson, President and CEO of
Oncolytics. REOLYSIN® has been well tolerated by the patients, and has demonstrated
activity in all trials reported on to date. Our current studies will allow us to design our pivotal
program based on Phase II data from human clinical studies.
Together with its collaborators, Oncolytics is now recruiting or enrolling patients in ten Phase
I/II or Phase II clinical trials with REOLYSIN® in the U.S. and the U.K., and has
permission to begin another Phase II trial in the U.S. These trials include four monotherapy
trials using REOLYSIN® alone, and seven trials using REOLYSIN® in combination
with radiation or chemotherapy.
Conference Call Details
Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call on Wednesday, July 16, 2008 at 11:30 a.m. MST (1:30 p.m. EST) to update investors on the Companys current and future
clinical program for REOLYSIN®.
To access the conference call by telephone, dial 1-416-644-3414 or 1-800-733-7571. A live audio
webcast will be available through the Companys website at www.oncolyticsbiotech.com. Please
connect at least 15 minutes prior to the webcast to ensure adequate time for any software download
that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will
also be available by telephone through July 23, 2008. To access the telephone replay, dial
1-416-640-1917 or 1-877-289-8525 and enter reservation number 21277892#.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Companys
belief as to the potential of
REOLYSIN®
as a cancer therapeutic, involve known and
unknown risks and uncertainties, which could cause the Companys actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of
REOLYSIN®
as a cancer treatment, the tolerability of
REOLYSIN®
outside a controlled test, the success and timely completion of clinical
studies and trials, the Companys ability to successfully commercialize REOLYSIN®,
uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Companys quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking
statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
|
|
Oncolytics Biotech Inc. |
|
The Equicom Group |
|
The Investor Relations Group |
Cathy Ward |
|
Nick Hurst |
|
Erika Moran |
210, 1167 Kensington Cr NW |
|
325, 300 5th Ave. SW |
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7 |
|
Calgary, Alberta, T2P 3C4 |
|
New York, NY 10004 |
Tel: 403.670.7377 |
|
Tel: 403.538.4845 |
|
Tel: 212.825.3210 |
Fax: 403.283.0858 |
|
Fax: 403.237.6916 |
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca |
|
nhurst@equicomgroup.com |
|
emoran@investorrelationsgroup.com |
-30-